NASDAQ:CALA

Calithera Biosciences Price Target, Predictions & Analyst Ratings

$0.20

-0.01 (-4.85%)

(As of 05/25/2022 04:00 PM ET)

Add

Compare

Today's Range: $0.19
▼
$0.22
50-Day Range: $0.16
▼
$0.63
52-Week Range: $0.15
▼
$2.59

Volume: 4.63 million shs
Average Volume: 2.75 million shs
Market Capitalization: $15.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 1.64

Calithera Biosciences (NASDAQ:CALA) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 4 Analyst Ratings

Analyst Price Target Consensus

$2.50
1,175.51% Upside

High PT	$4.00
Average PT	$2.50
Low PT	$1.50

Type	Current 5/26/21 to 5/26/22	1 Month Ago 4/26/21 to 4/26/22	3 Months Ago 2/25/21 to 2/25/22	1 Year Ago 5/26/20 to 5/26/21
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$2.50	$3.33	$3.67	$3.67
Price Target Upside	1,175.51% Upside	340.99% Upside	354.56% Upside	49.78% Upside

Get Calithera Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Calithera Biosciences (NASDAQ:CALA) vs. Its Competitors

Type	Calithera Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.72	2.52
Consensus Rating	Buy	Buy	Buy
Price Target Upside	1,175.51% Upside	472.33% Upside	26.78% Upside
News Sentiment Rating	Neutral News	Positive News	Neutral News
MarketBeat Community Rating	Outperform Votes 339 68.90% Underperform Votes 153 31.10%	Avg. Outperform Votes 171 67.06% Avg. Underperform Votes 84 32.94%	Avg. Outperform Votes 837 69.23% Avg. Underperform Votes 372 30.77%

Calithera Biosciences (NASDAQ:CALA) Analyst Ratings History

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/11/2022	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Price Target		$3.00 ➝ $1.50	+631.68%
4/4/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform	$3.00 ➝ $2.00	+444.80%
11/8/2021	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Swayampakula Ramakanth Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
11/5/2021	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
1/5/2021	Smith Barney Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Price Target		$10.00 ➝ $5.00	+90.84%
5/11/2020	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Price Target	Buy	$7.00 ➝ $10.00	+50.38%
3/27/2020	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$6.00	+34.23%

(Data available from 5/26/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Calithera Biosciences (NASDAQ:CALA) Analyst Ratings Frequently Asked Questions

What is Calithera Biosciences's consensus rating and price target?: According to the issued ratings of 4 analysts in the last year, the consensus rating for Calithera Biosciences stock is Buy based on the current 2 hold ratings and 2 buy ratings for CALA. The average twelve-month price target for Calithera Biosciences is $2.50 with a high price target of $4.00 and a low price target of $1.50. Learn more on CALA's analyst rating history.
Do Wall Street analysts like Calithera Biosciences more than its competitors?: Analysts like Calithera Biosciences stock less than the stock of other Medical companies. The consensus rating score for Calithera Biosciences is 2.50 while the average consensus rating score for medical companies is 2.72. Learn more on how CALA compares to other companies.
Do MarketBeat users like Calithera Biosciences more than its competitors?: MarketBeat users like Calithera Biosciences stock more than the stock of other Medical companies. 68.90% of MarketBeat users gave Calithera Biosciences an outperform vote while medical companies recieve an average of 67.06% outperform votes by MarketBeat users.

Does Calithera Biosciences's stock price have much upside?: According to analysts, Calithera Biosciences's stock has a predicted upside of 250.45% based on their 12-month price targets.
What analysts cover Calithera Biosciences?: Calithera Biosciences has been rated by LADENBURG THALM/SH SH, and SVB Leerink in the past 90 days.

This page was last updated on 5/26/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources